MSLN and pancreatic neoplasm: Although clinical trials of mesothelin-targeting agents have primarily focused on pleural mesothelioma, ovarian cancer, and pancreatic cancer, preliminary efficacy has been observed with certain mesothelin-targeting ADCs in cervical cancer patients.